SuperworthLENSAR price to sales ratio LNSR
Market value divided by revenue over the last twelve months, since 2021.
- Today, Oct 23, 2026
- 1.2×
- 5-year median
- 1.6×
- Against its 5-year history
- 37th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.6× to 3.3×
- Peer median
- 1.6×
LENSAR's price to sales ratio is 1.2× as of Oct 23, 2026.
That is below its 5-year median of 1.6×, close to the middle of its last 5 years.
Over that time it ranged from 0.6× in Nov 2023 to 3.3× in Mar 2025.
The median for 10 medical instruments and supplies stocks of a similar size is 1.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.2× | 1.1× | 2.6× |
| 2025 | 2.4× | 2.0× | 3.3× |
| 2024 | 2.0× | 0.8× | 2.0× |
| 2023 | 1.0× | 0.6× | 1.4× |
| 2022 | 0.9× | 0.8× | 2.5× |
| 2021 | 2.1× | 2.1× | 3.1× |
Against its peers
Companies in Medical - Instruments & Supplies nearest LENSAR's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| LNSRLENSAR | 1.2× |
| KEQUKewaunee Scientific | 0.3× |
| APTAlpha Pro Tech | 0.9× |
| NEPHNephros | 1.9× |
| PDEXPro DEX | 2.6× |
| UTMDUtah Medical Products | 6.5× |
| INFUInfuSystem | 1.9× |
| EMBCEmbecta | 0.4× |
| TCMDTactile Systems Technology | 1.5× |
| MDXGMimedx | 1.6× |
| MOVMovado | 1.0× |
| Peer median | 1.6× |
Where LENSAR ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on LENSAR
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.